Bernardo Stefanini

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

Antonio D’Alessio, Bernardo Stefanini, Julia Blanter et al. · The Lancet Oncology · 2024 · 65 citations · Full text

Medicine, Oncology, Pathology +17

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi et al. · Journal of Hepatology · 2023 · 63 citations · Full text

Medicine, Immunology, Oncology +17

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2023 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi et al. · Hepatology · 2024 · 54 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Lorenz Balcar, Bernhard Scheiner, Claudia Angela Maria Fulgenzi et al. · JHEP Reports · 2023 · 26 citations · Full text

Life Sciences, Immunology, Oncology +17